MedTrace Logo

Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms

NCT05993052 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-08-15

No results posted yet for this study

Summary

In around 90% of the patients with MPNs, an acquired mutation that promotes JAK/STAT signaling is identified \[3, 4\]. The JAK/STAT pathway transduces signals from cytokines including erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor.24 A point mutation that activates JAK2, JAK2V617F, is present in around 95% of patients with PV and 40% to 60% of patients with ET and MF

Conditions

  • Myeloproliferative Neoplasm

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Mahmoud Gaber · Sohag University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2023-08-31
Completion
2023-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05993052 on ClinicalTrials.gov